4BB 4basebio Plc

 
TIDM4BB 
 
25 May 2023 
 
4basebio PLC 
 
("4basebio", the "Company" or the "Group") 
 
4basebio and Neomatrix announce clinical material supply agreement to develop 
personalised cancer therapy utilising 4basebio's proprietary hpDNAT. 
 
Cambridge, UK , 25 May 2023 - 4basebio PLC (AIM: 4BB), an innovation driven 
biotechnology company enabling and accelerating development of advanced therapy 
medicinal products (ATMPs) through its high performant synthetic DNA products 
and non-viral, cell targeting nucleic acid delivery platform, today announces a 
product supply agreement with Neomatrix, an Italian based biotech company 
focused on personalised cancer immunotherapies. 
 
Under the agreement, 4basebio will supply clinical and preclinical DNA materials 
into Neomatrix' neoantigen cancer vaccine program. The program is expected to 
start patient enrolment in early 2024.  Neomatrix will gain access to 4basebio`s 
proprietary DNA products including hpDNAT and oeDNAT. 4basebio will manufacture 
and provide the personalised clinical grade DNA products, the key component in 
Neomatrix' immunotherapy cancer treatment. 
 
Neomatrix' vaccine based cancer treatment utilises the patient's immune system 
to recognise newly generated antigens (neoantigens), created by and displayed on 
tumour cells. Personalised cancer vaccines require a tumour biopsy which is 
sequenced to identify the neoantigens created by cancer-specific DNA mutations. 
A patient specific DNA sequence coding for such neoantigens is then designed, 
produced and administered. The time between initial biopsy and vaccine 
administration ("needle to needle") is critical. 4basebio's enzymatically 
produced synthetic DNA, with its rapid manufacturing timescales, is uniquely 
positioned to provide high performant DNA products in a timely fashion. 
 
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: "We are delighted to be 
working with Neomatrix in the delivery of neoantigen cancer vaccines. 4basebio's 
DNA products offer significant advantages both in terms of performance and the 
time required to manufacture a personalised vaccine, which is particularly 
relevant where needle to needle time is paramount to clinical outcome." 
 
Luigi Aurisicchio, CEO of Neomatrix, said: "We are excited to have 4basebio as 
our partner for the production of our personalised neoantigen vaccines. The 
performance and quality of 4basebio's DNA products as well as the speed of 
manufacture have driven our decision to partner with 4basebio." 
 
For further enquiries, please contact: 
 
4basebio PLC                                                         +44 (0)12 
2396 7943 
Heikki Lanckriet 
 
Nominated Adviser                                                +44 (0)20 7213 
0880 
Cairn Financial Advisers LLP 
Jo Tuner / Sandy Jamieson 
 
Broker                                                                     +44 
(0)20 7220 0500 
finnCap Ltd 
Geoff Nash / Richard Chambers / Charlotte Sutcliffe 
 
Lionsgate Communications (Media Enquiries)  +44 (0)77 91892509 
Jonathan Charles 
 
Notes to Editors 
 
About 4basebio 
 
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed 
on accelerating the development of advanced therapy medicinal products (ATMPs) 
through its high performant synthetic DNA products and non-viral, cell targeting 
nucleic acid delivery platform. The Company' objective is to become a market 
leader in the manufacture and supply of high quality synthetic DNA products for 
research, therapeutic and pharmacological use as well as development of target 
specific non-viral vectors for the efficient delivery of payloads in patients. 
The company is offering GMP compliant DNA starting materials suitable for use in 
AAV viral vector production as well as mRNA vaccine and therapeutics production. 
 
About Neomatrix 
 
Neomatrix is a biotech company with more than 15 years of experience and proven 
expertise in drug discovery in oncology and is recognised for the design and 
implementation of a number of innovative technologies, including that of DNA 
gene therapy. Neomatrix' core expertise is its experience in the prediction of 
neoantigens with an electroporation delivery system, a technology that can be 
used for a variety of clinically useful applications, from vaccine development 
to somatic gene therapy. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced by 
factors that could cause actual outcomes and results to be materially different. 
 
 
This information was brought to you by Cision http://news.cision.com 
 
 
END 
 
 

(END) Dow Jones Newswires

May 25, 2023 02:00 ET (06:00 GMT)

4basebio (LSE:4BB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

4basebio (LSE:4BB)
Gráfica de Acción Histórica
De May 2023 a May 2024